Unexpected toxicity following use of gemcitabine as a radiosensitizer in head and neck carcinomas: a veterinary radiation therapy oncology group pilot study

Gemcitabine (2′,2′‐difluorodeoxycytidine) was given intravenously twice weekly to 10 cats with oral squamous cell carcinoma and 15 dogs with nasal carcinoma undergoing radiotherapy as a radiosensitizing agent. The average total radiation dose was 50 Gy for dogs and 54 Gy for cats given Monday–Friday...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary radiology & ultrasound 2004-09, Vol.45 (5), p.466-470
Main Authors: LeBlanc, A.K, LaDue, T.A, Turrel, J.M, Klein, M.K
Format: Article
Language:English
Subjects:
adverse effects
Animals
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - veterinary
Cat Diseases - drug therapy
Cat Diseases - radiotherapy
Cats
Combined Modality Therapy
Deoxycytidine - administration & dosage
Deoxycytidine - adverse effects
Deoxycytidine - analogs & derivatives
Dog Diseases - drug therapy
Dog Diseases - radiotherapy
Dogs
drug toxicity
Female
gemcitabine
Head and Neck Neoplasms - drug therapy
Head and Neck Neoplasms - veterinary
Male
Radiation Dosage
Radiation-Sensitizing Agents - administration & dosage
Radiation-Sensitizing Agents - adverse effects
radiosensitizer
radiotherapy
veterinary
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gemcitabine (2′,2′‐difluorodeoxycytidine) was given intravenously twice weekly to 10 cats with oral squamous cell carcinoma and 15 dogs with nasal carcinoma undergoing radiotherapy as a radiosensitizing agent. The average total radiation dose was 50 Gy for dogs and 54 Gy for cats given Monday–Friday (planned dose of 54 and 57 Gy, respectively). Dogs received an average of five doses of gemcitabine beginning at 50 mg/m2, and cats received an average of five doses of gemcitabine beginning at 25 mg/m2. Twelve of 15 dogs and five of 10 cats required chemotherapy dose reduction or postponement because of hematologic or normal tissue toxicity. The results herein do not support the use of gemcitabine at the studied dose and schedule, as significant hematologic and local tissue toxicity was observed in the studied patients. Pharmacokinetic data are necessary to best define the efficacy and optimal dose and schedule of gemcitabine in combination with traditional radiotherapy.
ISSN:1058-8183
1740-8261
DOI:10.1111/j.1740-8261.2004.04080.x